Bracco Diagnostics

December 1, 2008 – At RSNA 2008, Bracco highlighted studies of its products that were the subject of multiple studies this past year, which reportedly demonstrated the company’s dedication to the manufacture of products that provide clinical safety and efficacy, including the following:

Over the past year, headlines across industry and consumer media have highlighted FDA warnings on the dangers of gadolinium-based contrast agents. To date, it has become common knowledge and a FDA black box warning that gadolinium-based agents run the risk of causing Nephrogenic Systemic Fibrosis or Nephrogenic Fibrosing Dermopathy (NSF/NFD).

This case is a routine coronary CTA with the focus on the coronary arteries. The patient was a middle-aged male with a family history of coronary artery disease, moderate risk profile and atypical chest pain. The EKG did not indicate myocardial ischemia and there was no enzyme leak.

The contrast agent Isovue, according to its manufacturer, is said to be a safe and effective nonionic contrast medium well established with U.S. clinical experience since 1986. Worldwide, more than 250 million doses of iopamidol have been administered.

Bracco's Isovue (iopamidol injection) X-ray/CT contrast is reportedly a safe and effective nonionic contrast agent, which is well established with U.S. clinical experience since 1986. Worldwide, more than 250 million doses of iopamidol have been administered, the company said.